Management of inflammatory bowel disease in children: It is time for an individualised approach

Area of Science:

• Pediatric Gastroenterology
• Inflammatory Bowel Disease Research
• Clinical Therapeutics

Background:

• Paediatric-onset inflammatory bowel disease (PO-IBD) presents with increased morbidity compared to adult-onset IBD.
• Individual patient outcomes vary, necessitating personalized management strategies.
• Balancing treatment risks and benefits is crucial for children and their families.

Purpose of the Study:

• To review risk factors associated with IBD progression in pediatric patients.
• To summarize current and emerging treatment options for PO-IBD.
• To discuss adverse event management and risk minimization strategies for pediatric IBD therapies.

Main Methods:

• Literature review of risk factors for PO-IBD progression.
• Summary of currently licensed and emerging therapies for pediatric IBD.
• Analysis of treatment-related adverse events and risk mitigation.

Main Results:

• Identified key risk factors influencing PO-IBD progression.
• Detailed current treatment landscape including Australian Pharmaceutical Benefit Scheme (PBS) listings.
• Highlighted promising therapies in adult trials for potential pediatric application.

Conclusions:

• Optimizing management of PO-IBD requires understanding individual risk factors.
• A comprehensive approach integrating risk assessment, current therapies, and novel treatments is essential.
• The long-term goal of intestinal healing guides modern PO-IBD management strategies.